CHROMATOGRAPHY 53
Bridging the gap between drugs and regulatory bodies
It’s time to change the way pharmaceutical companies and regulatory authorities communicate, says Dr Imre Molnár.
W
e have more than 100,000 diseases but drugs are available for
just 20,000 of them. Terefore 80,000 diseases have no support from big pharma because it is too expensive to develop new drugs. It takes 10 development projects to bring one new drug to the market; nine projects are dying due to high costs. In 2002, this discrepancy prompted regulatory agencies to try to change the situation. Instead of developing drugs by trial and error, it was decreed that solid science should be applied and that planned design of experiments (DoE) should be developed and conducted.
Fig. 1. How modeling tools improve communication between players in the pharmaceutical sector.
Since the introduction of quality by design (QbD) principles by the US Food and Drug Administration (FDA) more than 10 years ago, brought forward by Dr Moheb Nasr and his colleagues, a number of things have changed. Instead of submitting a large set of ‘raw data’, the submission itself has become a more scientific document – explaining how the analytical part of the process was developed, what is critical, what
will likely be improved in the process later on and how that will be managed. Risk assessment tools were applied and the basics of a control strategy for the process have been further developed.
All of the above was enhanced and supported by a better understanding of the principles of modern ultra-high performance liquid chromatography (UHPLC), especially by better communicating details of the chromatographic separation process, which is the foundation of good analytical practice and responsible for reliable quality control. Tis progress became possible using the capabilities of modelling tools such as the DryLab software, among others. DryLab could visualise a change in a separation by showing the corresponding chromatogram in only one second, in this way contributing to further improvements in column technologies, to higher speeds and to novel instrumentation principles, such as the UPLC line from Waters. Tis helped to speed up the exchange of information by faster analysis times, and later on, with the UHPLC lines from Agilent, Shimadzu and others.
Te analysis time of a drug has now evolved from 50 to 160 minutes down to three to five minutes using DryLab1,2
. We
are able to better communicate about new drugs using computer modelling to explain precisely how the method was developed in line with the current best practice. Te common workhorse in the pharmaceutical industry is usually still reversed- phase high-performance liquid chromatography (HPLC), and it is important that we understand why out-of-specifications (OoS) occur and how we can correct them without costly bureaucracy. In this way, we can convince the regulatory partners about the science in our methods easier and faster. Only by following this path are we able to get new drugs onto the market for smaller populations of patients, who are waiting desperately for help.
For more information ✔ at
www.scientistlive.com/eurolab
Dr Imre Molnár is president of the Molnár-Institute in Berlin, Germany.
www.molnar-institut.com
REFERENCES: 1
Using an innovative Quality- by-Design approach for development of a stability indicating UHPLC method for Ebastine in the API and pharmaceutical formulations, Alexander Schmidt, Imre Molnár, J. Pharm. Biomed. Anal., 78-79 (2013), 65-74.
2
Exploring better column selectivity choices in ultra- high performance liquid chromatography using Quality by Design principles, Róbert Kormány, Imre Molnár, Hans-Jürgen Rieger, J. Pharm. Biomed. Anal., 80 (2013), 79-88.
www.scientistlive.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92